544 terminated. 544 Phase 2, 167 Phase 1, 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 544 | Terminated 544 |
| Phase 1 | 167 | Terminated 167 |
| Phase 3 | 12 | Terminated 12 |
Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NG2 and DLL3 CAR-T Cells Targeting Melanoma NG2 and DLL3 CAR-T cells - Melanoma | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-09-01 | 2026-11-03 |
| Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) Acasunlimab, Pembrolizumab - Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID) | Phase 2 | Terminated | Genmab | 1 | 2025-07-25 | 2026-09-30 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-13 | 2026-02-25 |
| Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter Ropidoxuridine - Glioblastoma, IDH-wildtype | Phase 2 | Terminated | Shuttle Pharmaceuticals, Inc. | 30 | 2024-09-02 | 2025-12-18 |
| Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases Lutathera - Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2 | Phase 2 | Terminated | Imperial College London | 1 | 2024-08-02 | 2026-01-14 |
| A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients Cannabidiol (CBD), Placebo - Glioblastoma | Phase 2 | Terminated | Mclean Hospital | 2 | 2024-02-15 | 2026-03-16 |
| IMM60 and Pembrolizumab in Melanoma and NSCLC IMM60, Pembrolizumab - Non-small Cell Lung Cancer, Melanoma | Phase 1 / Phase 2 | Terminated | iOx Therapeutics | 1 | 2023-11-15 | 2024-04-24 |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive INCB099280 - Advanced Solid Tumor | Phase 2 | Terminated | Incyte Corporation | 73 | 2023-10-30 | 2026-10-20 |
| A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma encorafenib, binimetinib, pembrolizumab - Melanoma | Phase 2 | Terminated | Pfizer | 38 | 2023-06-13 | 2026-03-09 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors Rigosertib, Pembrolizumab, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 7 | 2023-05-09 | 2026-09-16 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| CD8 Minibody Repeatability Study Zirconium 89Zr crefmirlimab berdoxam - Melanoma, Renal Cell Carcinoma | Phase 2 | Terminated | ImaginAb, Inc. | 3 | 2023-02-16 | 2024-12-03 |
| A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS) - Recurrent GBM | Phase 1 / Phase 2 | Terminated | SonALAsense, Inc. | 8 | 2023-02-06 | 2024-07-26 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Terminated | Fox Chase Cancer Center | 20 | 2022-12-21 | 2025-07-30 |
| Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) Berubicin Hydrochloride - Recurrent Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | WPD Pharmaceuticals Sp. z o.o. | 5 | 2022-12-07 | 2024-06-06 |
| Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq - Recurrent High-grade Glioma, Recurrent Glioblastoma | Phase 1 / Phase 2 | Terminated | Dawonmedax Co., Ltd. | 7 | 2022-12-05 | 2025-02-21 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
Showing 20 of 544. Sign in to see all of them.
Melanoma (260) · Glioblastoma (123) · Brain Neoplasms (64) · Glioma (61) · Neoplasm Metastasis (42) · Astrocytoma (40) · Carcinoma, Non-Small-Cell Lung (37) · Gliosarcoma (35) · Neoplasms (32) · Carcinoma, Renal Cell (29) · Neuroblastoma (27) · Neuroendocrine Tumors (26) · Skin Neoplasms (23) · Oligodendroglioma (22) · Sarcoma (22)
Neoplasms by Histologic Type (543) · Neuroectodermal Tumors (522) · Neoplasms, Germ Cell and Embryonal (520) · Neoplasms (512) · Neoplasms by Site (383) · Neuroendocrine Tumors (300) · Neoplasms, Glandular and Epithelial (278) · Nevi and Melanomas (270) · Skin and Connective Tissue Diseases (269) · Skin Diseases (268) · Skin Neoplasms (238) · Neoplasms, Neuroepithelial (206) · Nervous System Diseases (118) · Nervous System Neoplasms (111)
Temozolomide (49) · pembrolizumab (43) · Cyclophosphamide (36) · Nivolumab (32) · Ipilimumab (30) · aldesleukin (28) · Bevacizumab (25) · Radiotherapy (21) · Interleukin-2 (19) · fludarabine (18) · fludarabine phosphate (18) · Vemurafenib (12) · Everolimus (11) · Irinotecan (11) · Radiosurgery (11)
National Cancer Institute (NCI) (55) · M.D. Anderson Cancer Center (19) · Novartis Pharmaceuticals (11) · Burzynski Research Institute (10) · University of California, San Francisco (9) · H. Lee Moffitt Cancer Center and Research Institute (8) · Incyte Corporation (7) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · Dana-Farber Cancer Institute (6) · Vanderbilt-Ingram Cancer Center (6) · Fred Hutchinson Cancer Center (5) · National Institutes of Health Clinical Center (CC) (5) · Pfizer (5) · University of Utah (5) · Bristol-Myers Squibb (4)
United States (422) · France (41) · United Kingdom (41) · Germany (38) · Spain (38) · Australia (32) · Italy (31) · Canada (30) · Belgium (20) · Netherlands (20) · Switzerland (17) · Denmark (14) · South Korea (13) · Poland (9) · Taiwan (9)
Steven A Rosenberg, M.D. (14) · Stanislaw R. Burzynski, MD, PhD (10) · Annick Desjardins, MD, FRCPC (3) · Steven Rosenberg, M.D. (3) · Thomas Gajewski (3) · Adil Daud, M.D. (2) · Allen K Sills, MD (2)
PMID 31401903, PMID 38335473, PMID 39462179, PMID 12749708, PMID 15337804, PMID 16648043, PMID 17293590, PMID 18425516, PMID 18447671, PMID 18797818, PMID 20030854, PMID 20042969, PMID 20967484, PMID 21516509, PMID 21865400, PMID 22028492, PMID 22056381, PMID 22431777, PMID 22555974, PMID 22682017, PMID 23377668, PMID 23633099, PMID 23861247, PMID 24801836, PMID 25062770, PMID 25086465, PMID 25105369, PMID 25250858, PMID 25252722, PMID 25432172, PMID 25695689, PMID 25797743, PMID 25991462, PMID 26500235, PMID 26678657, PMID 27223498, PMID 27232884, PMID 27252174, PMID 27261467, PMID 27330808, PMID 27362300, PMID 28395880, PMID 28915798, PMID 29100190, PMID 29177094, PMID 29242283, PMID 29445030, PMID 29721378, PMID 29741745, PMID 30151703
2009 (8), 2018 (7), 2015 (6), 2017 (6), 2023 (4), P30CA015704 (4), 2016 (3), P30CA015083 (3), P30CA033572 (3), U10CA032102 (3), 2008 (2), 2014 (2), N01CM00039 (2), N01CM62205 (2), P30CA006973 (2)